http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2701453-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbf61f0173077fff7e02f5a474c3cb7b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2814 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2011-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66ca3bb88bd17d90d947e29de727b380 |
| publicationDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2701453-T3 |
| titleOfInvention | Procedure for the diagnosis or pre-diagnosis of a β-amyloidopathy |
| abstract | Procedure for the diagnosis or prediagnosis of ß-amyloidopathy, Alzheimer's dementia, which occurs with a deposition of brain protein and reduced activity of the brain ABCC1 transporter, or for establishing the risk of a subject suffering from such disease, by ingesting the subject substances that are transported through the cerebral ABCC1 transporter, consisting of the following stages: a) determination of the amount of the substance ingested in samples of the subject's body fluid at a given time; b) repetition of the determination of step a) at least at another later time; c) Comparison of the amounts established in steps a) and b) with amounts that had been defined at the same time as characteristics of subjects who at the time of sampling did not show clinical signs of Alzheimer ß-amyloidopathy, being selected substances that are transported through the brain ABCC1 transporter of antibiotics, virostatics / antiviral drugs, antiallergics / antihistamines, cardiovascular drugs, antidepressants, anti-hyperuremic drugs, cytostatic drugs, vitamins / vitamin analogs, antiphlogistics, antiepileptics, hormones / hormone derivatives , leukotrienes, fluorescent samples, metabolites coupled to GSH, sulfate or glucuronide of natural substances (produced endogenously), toxins or drugs selected from the group consisting of 2,4-dinitrophenyl-SG, biman-SG, N-ethylmaleimide-SG, doxorubicin-SG, thiotepa-SG, cyclophosphamide-SG, melphalan-SG, chlorambucil-SG, Ethacrinic acid-SG, metolachlor-SG, atrazine-SG, sulforafan-SG, aflatoxin B1-epoxide-SG, 1- 4-nitroquinoline-SG oxide, As (SG) 3, etoposide-gluc, 4- (methylnitrosamino) - 1- (3-pyridyl) -1-butanol (NNAL) -3ß-O20 gluc, SN-38-gluc, 4-methylumbelliferyl-ß-d-gluc, 6-hydroxy-5,7-dimethyl-2- sulfate methylamino-4- (3-pyridylmethyl) -benzothiazole (E3040S) -gluc, leukotriene C4, prostaglandin A2-SG, 15-deoxy-Δ12,14 prostaglandin J2-SG, hydroxynonenal-SG, 17ß-estradiol-17-ß-d -gluc, glucuronosylbilirubin, bis-lucuronosylbilirubin, hiodeoxycholate-6-α-gluc, estrone-3 sulfate, dehydroepiandrosterone sulfate, sulphatolitholate. |
| priorityDate | 2010-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 169.